or Try an Advanced Search...

    Technical Analysis for ARGX - argenx SE

    Grade Last Price % Change Price Change
    F 360.23 0.51% 1.82
    ARGX closed up 0.51 percent on Friday, April 19, 2024, on 1.29 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 9
    *** please verify all earnings dates ***
    6 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ARGX trend table...
    Date Alert Name Type % Chg
    Pocket Pivot Bullish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Doji - Bullish? Reversal 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    180 Bearish Setup Bearish Swing Setup 0.51%
    Below Lower BB Weakness 0.51%
    Down 3 Days in a Row Weakness 0.51%
    Down 4 Days in a Row Weakness 0.51%
    Down 5 Days in a Row Weakness 0.51%
    Older End-of-Day Signals for ARGX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 14 hours ago
    60 Minute Opening Range Breakdown about 16 hours ago
    Bearish 180 Entry about 16 hours ago
    Fell Below Previous Day's Low about 16 hours ago
    Up 1% about 18 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ARGX Chart by TradingView
    Basic chart:

    Profile

    argenx SE Description

    argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Disease Cancer Immunotherapy Inflammation Lymphoma Acute Myeloid Leukemia Rheumatoid Arthritis Lipid Myelodysplastic Syndrome Treatment Of Autoimmune Disease Myasthenia Gravis Dyslipidemia Hematological Cancers Myasthenia Thrombocytopenia Skin Inflammation Janus Kinase Inhibitor Rgx Therapies For The Treatment Of Autoimmune Diseases Treatment Of Hematological Cancers

    Is ARGX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
    Apr 10 Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
    Mar 29 Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4
    Mar 27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
    Mar 26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024
    Mar 26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
    Mar 22 Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
    Mar 22 Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
    Mar 21 Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
    Mar 21 Argenx gains after setback to Roche/Chugai myasthenia gravis therapy
    See more ARGX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 550.76
    52 Week Low 327.73
    Average Volume 250,006
    200-Day Moving Average 443.76
    50-Day Moving Average 387.65
    20-Day Moving Average 385.05
    10-Day Moving Average 374.31
    Average True Range 9.84
    RSI (14) 31.51
    ADX 15.18
    +DI 16.58
    -DI 28.72
    Chandelier Exit (Long, 3 ATRs) 381.72
    Chandelier Exit (Short, 3 ATRs) 379.37
    Upper Bollinger Bands 411.28
    Lower Bollinger Band 358.81
    Percent B (%b) 0.03
    BandWidth 13.63
    MACD Line -6.51
    MACD Signal Line -3.38
    MACD Histogram -3.127
    Fundamentals Value
    Market Cap 21.32 Billion
    Num Shares 59.2 Million
    EPS -4.10
    Price-to-Earnings (P/E) Ratio -87.86
    Price-to-Sales 23.10
    Price-to-Book 8.32
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 367.66
    Resistance 3 (R3) 367.59 365.04 366.42
    Resistance 2 (R2) 365.04 363.15 365.08 366.00
    Resistance 1 (R1) 362.64 361.98 361.37 362.71 365.59
    Pivot Point 360.09 360.09 359.46 360.13 360.09
    Support 1 (S1) 357.69 358.20 356.42 357.76 354.87
    Support 2 (S2) 355.14 357.03 355.18 354.46
    Support 3 (S3) 352.74 355.14 354.04
    Support 4 (S4) 352.81